Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18807953 | Medical Companion Application with Integrated AI Technologies, Extended Reality, and Decentralized Health Data Marketplace and Related Methods | August 2024 | March 2026 | Abandon | 19 | 1 | 0 | No | No |
| 18792249 | DYNAMIC ACTIVITY RECOMMENDATION USING MACHINE LEARNING AND GEOFENCING IN A MENTAL WELLNESS APPLICATION | August 2024 | March 2026 | Abandon | 19 | 1 | 0 | No | No |
| 18725376 | DIGITAL MEDICINE COMPANION FOR CDK INHIBITOR MEDICATIONS FOR CANCER PATIENTS | June 2024 | March 2026 | Abandon | 20 | 1 | 0 | No | No |
| 18692401 | A COMPUTER-IMPLEMENTED METHOD FOR PROVIDING CARE | March 2024 | January 2026 | Abandon | 22 | 1 | 0 | No | No |
| 18453802 | PREDICTING RISK OF PREGNANCY-RELATED COMPLICATIONS USING MACHINE LEARNING | August 2023 | September 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18351759 | ADAPTIVE PATIENT CONDITION SURGICAL WARNING SYSTEM | July 2023 | February 2026 | Allow | 31 | 1 | 0 | No | No |
| 18025466 | DETERMINATION APPARATUS | March 2023 | May 2025 | Abandon | 26 | 1 | 0 | Yes | No |
| 18117833 | METHOD OF DOCUMENTING EXPOSURE TO INFECTED PATIENTS | March 2023 | June 2025 | Abandon | 27 | 2 | 0 | No | No |
| 18173319 | SENTIMENT-BASED ANALYTICS MANAGEMENT SYSTEMS AND METHODS | February 2023 | March 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18085812 | SYSTEMS AND METHODS FOR AUTOMATING WORKFLOWS | December 2022 | November 2025 | Allow | 35 | 3 | 0 | Yes | No |
| 17926741 | ACUTE LIVER PATIENT MANAGEMENT | November 2022 | September 2025 | Abandon | 34 | 2 | 0 | No | No |
| 18054669 | Medical Video Charting Application | November 2022 | March 2025 | Abandon | 28 | 2 | 0 | No | No |
| 17997667 | ARTIFICIAL INTELLIGENCE-BASED SYSTEMS AND METHODS FOR DOSING OF PHARMACOLOGIC AGENTS | November 2022 | May 2025 | Abandon | 30 | 1 | 1 | No | No |
| 17964871 | PHARMACEUTICAL ADMINISTRATION TRACKING AND TREATMENT COMPLIANCE SYSTEM | October 2022 | February 2025 | Abandon | 28 | 1 | 0 | No | No |
| 17946975 | PREDICTING SUBJECTIVE RECOVERY FROM ACUTE EVENTS USING CONSUMER WEARABLES | September 2022 | October 2025 | Abandon | 37 | 5 | 0 | Yes | No |
| 17819637 | STORAGE MEDIUM, DISPLAY CONTROL DEVICE, AND MEDICAL IMAGE DISPLAY SYSTEM | August 2022 | December 2025 | Abandon | 40 | 3 | 0 | Yes | No |
| 17819437 | METHOD AND SYSTEM AND APPARATUS FOR QUANTIFYING UNCERTAINTY FOR MEDICAL IMAGE ASSESSMENT | August 2022 | March 2026 | Abandon | 43 | 4 | 0 | No | No |
| 17817962 | RISK ASSESSMENT AND INTERVENTION PLATFORM ARCHITECTURE FOR PREDICTING AND REDUCING NEGATIVE OUTCOMES IN CLINICAL TRIALS | August 2022 | October 2025 | Abandon | 39 | 3 | 0 | Yes | No |
| 17880327 | BILLING FOR SUCCESSFUL IVF TREATMENT | August 2022 | September 2025 | Abandon | 37 | 2 | 0 | Yes | No |
| 17877666 | Method and system for assessing disease progression | July 2022 | November 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17815888 | HEALTH APPLICATION | July 2022 | April 2025 | Abandon | 32 | 2 | 0 | Yes | No |
| 17841688 | METHOD, APPARATUS, DEVICE AND MEDIUM FOR MEDICATION DECISION SUPPORT BASED ON GRAPHICS STATE MACHINE | June 2022 | September 2025 | Abandon | 39 | 2 | 0 | No | No |
| 17826103 | MACHINE LEARNING ANALYSIS OF DATABASES | May 2022 | October 2025 | Abandon | 41 | 4 | 0 | Yes | No |
| 17741151 | METHOD AND APPARATUS OF CALCULATING COMPREHENSIVE DISEASE INDEX | May 2022 | February 2025 | Abandon | 33 | 2 | 0 | No | No |
| 17716664 | E-HEALTH INSIGHTS OF WHOLE BODY VIBRATION HEALTH MONITORING | April 2022 | March 2025 | Abandon | 35 | 2 | 0 | Yes | No |
| 17767637 | PROVIDING A VISUAL REPRESENTATION OF PATIENT MONITORING DATA | April 2022 | October 2025 | Allow | 42 | 2 | 0 | No | No |
| 17715703 | METHODS AND SYSTEMS FOR SCHEDULING A PATIENT-SPECIFIC IMMUNOTHERAPY PROCEDURE | April 2022 | March 2025 | Abandon | 35 | 3 | 0 | No | No |
| 17711615 | METHODS, SYSTEMS, APPARATUSES, AND DEVICES FOR FACILITATING MANAGING ADMINISTERING OF PSYCHEDELIC DRUGS TO USERS | April 2022 | January 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17707892 | DYNAMIC ADMINISTRATIVE SYSTEM FOR HEALTHCARE AND TELEHEALTH MANAGEMENT | March 2022 | November 2025 | Abandon | 44 | 3 | 0 | No | No |
| 17691829 | MEDICAMENT DELIVERY DEVICE WITH AN ADJUSTABLE AND PIECEWISE ANALYTE LEVEL COST COMPONENT TO ADDRESS PERSISTENT POSITIVE ANALYTE LEVEL EXCURSIONS | March 2022 | June 2025 | Allow | 39 | 2 | 0 | No | No |
| 17630729 | SYSTEM AND METHOD FOR MONITORING ENERGY USAGE TO ANALYZE PATIENT HEALTH | January 2022 | March 2026 | Abandon | 49 | 4 | 0 | Yes | No |
| 17626251 | CLOUD-BASED SYSTEM AND METHOD FOR CLAIMING INSURANCE FOR OUT-OF-POCKET MEDICAL EXPENSES | January 2022 | November 2024 | Abandon | 34 | 2 | 0 | Yes | No |
| 17647025 | DIGITAL DOCUMENT ASSISTANT FOR ORGANIZING MEDICAL INFORMATION | January 2022 | January 2026 | Abandon | 49 | 2 | 0 | Yes | No |
| 17646621 | Methods to Assess Clinical Outcome Based Upon Updated Probabilities and Treatments Thereof | December 2021 | February 2026 | Abandon | 50 | 4 | 0 | Yes | No |
| 17492058 | SYSTEMS AND METHODS FOR MEDICATION MANAGEMENT | October 2021 | September 2025 | Abandon | 48 | 4 | 0 | Yes | Yes |
| 17418642 | ENHANCED COMPUTATIONAL HEART SIMULATIONS | June 2021 | October 2025 | Allow | 52 | 3 | 0 | No | No |
| 17318457 | METHOD FOR INTERFACING MEDICAL INFORMATION BETWEEN A MEDICAL INFORMATION EXCHANGE AND COMPUTING ENTITIES | May 2021 | January 2025 | Abandon | 44 | 7 | 0 | Yes | No |
| 17201992 | APPARATUS AND METHODS FOR TRACKING ADMINISTERING OF MEDICATION BY MEDICATION INJECTION DEVICES | March 2021 | November 2024 | Abandon | 44 | 4 | 0 | No | No |
| 17200375 | PROVIDING AUXILIARY INFORMATION REGARDING HEALTHCARE PROCEDURE AND SYSTEM PERFORMANCE USING AUGMENTED REALITY | March 2021 | November 2025 | Abandon | 56 | 6 | 0 | Yes | No |
| 17192313 | METHOD AND SYSTEM FOR SUPPORTING HF AND/OR US SURGICAL PROCEDURES AND SOFTWARE PROGRAM PRODUCT | March 2021 | February 2025 | Allow | 47 | 4 | 0 | Yes | No |
| 17163435 | COLLABORATIVE TRIAL DESIGN PLATFORM | January 2021 | October 2024 | Abandon | 45 | 1 | 0 | No | No |
| 17105097 | SYSTEM AND METHOD FOR DATA PROVIDER TRACKING AND MONETIZATION | November 2020 | August 2025 | Allow | 56 | 3 | 1 | No | No |
| 16951436 | Event Data Modelling | November 2020 | October 2024 | Allow | 47 | 3 | 0 | Yes | No |
| 17087361 | SYSTEMS, METHODS, AND COMPUTER-READABLE MEDIUM FOR MANAGING A DATABASE DURING AN EXAMINATION | November 2020 | January 2025 | Abandon | 50 | 4 | 0 | Yes | No |
| 17001463 | COMPUTER-IMPLEMENTED METHOD AND COMPUTING DEVICE FOR PREDICTING CANCER | August 2020 | February 2026 | Abandon | 60 | 6 | 0 | Yes | No |
| 16954443 | SYSTEM AND METHOD FOR PROCESSING PATIENT-RELATED MEDICAL DATA | June 2020 | July 2025 | Allow | 60 | 7 | 0 | No | No |
| 16891069 | GENERATION OF DATASETS FOR MACHINE LEARNING MODELS AND AUTOMATED PREDICTIVE MODELING OF OCULAR SURFACE DISEASE | June 2020 | October 2024 | Allow | 52 | 4 | 0 | Yes | No |
| 16731274 | PATIENT SAFETY USING VIRTUAL OBSERVATION | December 2019 | July 2024 | Allow | 54 | 3 | 0 | Yes | No |
| 16613483 | METHOD AND APPARATUS FOR GENERATING TREATMENT REGIMENS | November 2019 | March 2025 | Abandon | 60 | 6 | 0 | Yes | No |
| 16677623 | Providing a Continuity of Care Across Multiple Care Settings | November 2019 | March 2025 | Allow | 60 | 9 | 0 | Yes | No |
| 16677217 | METHOD AND SYSTEM FOR GENERATING STANDARDIZED CODES FROM ELECTRONIC RECORDS | November 2019 | January 2023 | Abandon | 38 | 7 | 0 | No | No |
| 16610484 | DRUG DISPENSING DEVICE, CONTROL PROGRAM FOR DRUG DISPENSING DEVICE, AND RECORDING MEDIUM WITH RECORDED CONTROL PROGRAM | November 2019 | January 2025 | Abandon | 60 | 7 | 0 | No | No |
| 16544016 | E-TRIAGE: AN ELECTRONIC EMERGENCY TRIAGE SYSTEM | August 2019 | July 2024 | Allow | 59 | 8 | 0 | Yes | No |
| 15767240 | SYSTEMS AND METHODS FOR GENERATING CORRECT RADIOLOGICAL RECOMMENDATIONS | April 2018 | August 2024 | Allow | 60 | 8 | 0 | Yes | No |
| 15826049 | EFFECTIVE PATIENT STATE SHARING | November 2017 | September 2025 | Abandon | 60 | 8 | 0 | Yes | No |
| 15590997 | PATIENT TREATMENT SYSTEMS AND METHODS | May 2017 | December 2020 | Abandon | 43 | 8 | 0 | Yes | Yes |
| 15377216 | SYSTEMS AND METHODS FOR REMOTE AND HOST MONITORING COMMUNICATIONS | December 2016 | January 2025 | Abandon | 60 | 6 | 0 | Yes | Yes |
| 15295741 | COHORT DETECTION FROM MULTIMODAL DATA AND MACHINE LEARNING | October 2016 | February 2026 | Abandon | 60 | 12 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SANGHERA, STEVEN G.S..
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SANGHERA, STEVEN G.S. works in Art Unit 3684 and has examined 25 patent applications in our dataset. With an allowance rate of 40.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 54 months.
Examiner SANGHERA, STEVEN G.S.'s allowance rate of 40.0% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SANGHERA, STEVEN G.S. receive 5.68 office actions before reaching final disposition. This places the examiner in the 100% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by SANGHERA, STEVEN G.S. is 54 months. This places the examiner in the 3% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a -4.0% benefit to allowance rate for applications examined by SANGHERA, STEVEN G.S.. This interview benefit is in the 6% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 8.6% of applications are subsequently allowed. This success rate is in the 4% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 3.1% of cases where such amendments are filed. This entry rate is in the 4% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 20% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 0.0% of appeals filed. This is in the 2% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 72.7% are granted (fully or in part). This grant rate is in the 79% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 40% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 43% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.